SA
Create Free Alerts
Ascendis Pharma A/SASNDNASDAQ
Loading
OverviewIntelligenceChartsNews

Latest News

New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52
globenewswire.com

New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52

- Annualized height velocity of 9.05 cm/year (LS mean) for TransCon hGH-treated children was similar at Week 52 to daily somatropin-treated children  - TransCon hGH showed a safety and tolerability profile comparable to daily somatropin with no occurrences of slipped capital femoral epiphysis (SCFE) COPENHAGEN, Denmark, March 17, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced positive Week 52 topline results from New InsiGHTS, its Phase 2 randomized, open-label, active-controlled trial in the U.S. investigating the safety, tolerability, and efficacy of once-weekly TransCon hGH (lonapegsomatropin; U.S. FDA-approved for pediatric and adult growth hormone deficiency (GHD) and approved in other territories for pediatric GHD) compared to daily somatropin in prepubertal children with Turner syndrome. New InsiGHTS randomized and dosed 49 children with Turner syndrome aged 1 to 10 years old.

Bamco Inc. NY Makes New $1.11 Million Investment in Ascendis Pharma A/S $ASND
defenseworld.net

Bamco Inc. NY Makes New $1.11 Million Investment in Ascendis Pharma A/S $ASND

Bamco Inc. NY bought a new stake in shares of Ascendis Pharma A/S (NASDAQ: ASND) during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 5,600 shares of the biotechnology company's stock, valued at approximately $1,113,000. A number of other institutional

New Two-Year Data from Pivotal ApproaCH Trial Showing Durable Benefits of TransCon® CNP (Navepegritide) in Children with Achondroplasia Shared at ACMG 2026
globenewswire.com

New Two-Year Data from Pivotal ApproaCH Trial Showing Durable Benefits of TransCon® CNP (Navepegritide) in Children with Achondroplasia Shared at ACMG 2026

COPENHAGEN, Denmark, March 16, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from its pivotal ApproaCH Trial showing that children with achondroplasia treated with once-weekly TransCon CNP (navepegritide) maintained consistent improvements in growth through Week 104, with further improvement in body proportionality during the second year of treatment. These and other results were shared in an oral presentation by Dr. Ravi Savarirayan, M.B.B.S.

Ally Bridge Group NY LLC Acquires Shares of 51,080 Ascendis Pharma A/S $ASND
defenseworld.net

Ally Bridge Group NY LLC Acquires Shares of 51,080 Ascendis Pharma A/S $ASND

Ally Bridge Group NY LLC bought a new position in shares of Ascendis Pharma A/S (NASDAQ: ASND) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 51,080 shares of the biotechnology company's stock, valued at approximately $10,155,000. Ascendis Pharma A/S comprises

Invesco Main Street Mid Cap Fund Q4 2025 Portfolio Activity
seekingalpha.com

Invesco Main Street Mid Cap Fund Q4 2025 Portfolio Activity

We maintain our valuation discipline and our focus on companies with competitive advantages and skilled management teams that we believe are executing better than their peers. We initiated a position in Tractor Supply after recent share weakness created a compelling entry point, in our view. Tyler Technologies was sold because the software provider's revenue growth has decelerated, which reduced our conviction in its upside potential.

Barometer Capital Management Inc. Buys 2,900 Shares of Ascendis Pharma A/S $ASND
defenseworld.net

Barometer Capital Management Inc. Buys 2,900 Shares of Ascendis Pharma A/S $ASND

Barometer Capital Management Inc. increased its position in Ascendis Pharma A/S (NASDAQ: ASND) by 288.8% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,904 shares of the biotechnology company's stock after purchasing an additional 2,900 shares during

Ascendis Pharma: Yuviwel Approved Despite Legal Challenges
seekingalpha.com

Ascendis Pharma: Yuviwel Approved Despite Legal Challenges

Ascendis Pharma secured FDA approval for Yuviwel in achondroplasia, despite ongoing legal challenges from BioMarin. I expect Yuviwel's U.S. sales to be modest, with stronger international growth potential starting next year, but also meaningful competition from BridgeBio's infigratinib. The Yuviwel and Skytrofa combination demonstrates superior efficacy, positioning ASND for potential blockbuster sales in achondroplasia and other growth disorders over the long term.

American Century Companies Inc. Buys 13,797 Shares of Ascendis Pharma A/S $ASND
defenseworld.net

American Century Companies Inc. Buys 13,797 Shares of Ascendis Pharma A/S $ASND

American Century Companies Inc. lifted its stake in shares of Ascendis Pharma A/S (NASDAQ: ASND) by 2.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 544,606 shares of the biotechnology company's stock after purchasing an additional 13,797 shares during the

FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older
globenewswire.com

FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older

COPENHAGEN, Denmark, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FDA) has granted approval under the FDA's Accelerated Approval Program for YUVIWEL® (navepegritide; developed as TransCon® CNP), the first and only once-weekly treatment indicated to increase linear growth in children 2 years of age and older with achondroplasia with open epiphyses and the only one to provide continuous systemic exposure to CNP over the weekly dosing interval. Continued approval for this indication, which was based on an improvement in annualized growth velocity (AGV), may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

Artisan Partners Limited Partnership Has $739.75 Million Stock Position in Ascendis Pharma A/S $ASND
defenseworld.net

Artisan Partners Limited Partnership Has $739.75 Million Stock Position in Ascendis Pharma A/S $ASND

Artisan Partners Limited Partnership lowered its position in Ascendis Pharma A/S (NASDAQ: ASND) by 6.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,720,880 shares of the biotechnology company's stock after selling 269,544 shares during the quarter. Ascendis

Ascendis Pharma FY 2025 Results: More Than A Takeover Story
seekingalpha.com

Ascendis Pharma FY 2025 Results: More Than A Takeover Story

Ascendis Pharma has transitioned into a revenue-scaled commercial biotech, driven by Yorvipath's rapid adoption and strong FY25 results. ASND's 2025 product revenue surged to €684 million, with Yorvipath accounting for nearly 70% and operating profit turning positive in 4Q25. TransCon CNP's upcoming FDA decision is a major catalyst, but ASND now offers multiple commercial drivers, reducing binary risk.

Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026
globenewswire.com

Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026

COPENHAGEN, Denmark, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report full year 2025 financial results and provide a business update on Wednesday, February 11, 2026, after the close of the U.S. financial markets. Ascendis Pharma also plans to host a conference call and live webcast on February 11, 2026, at 4:30 p.m.

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance